How does MYCN change the way genetic information is read?
Understanding how the MYCN protein changes the amounts of other proteins in the cell by changing the way DNA is processed and translated.
Protecting young hearts from chemotherapy-related heart problems
Investigating whether giving a medicine before doxorubicin cancer treatment could prevent heart damage.
Understanding what the red flags are in aggressive neuroblastoma to improve and develop treatments
Finding out which changes to how DNA is read in neuroblastoma can give doctors more information about the cancer, and investigating whether these changes could be stopped through medicines.
Targeting a relapse causing protein to treat childhood acute myeloid leukaemia
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
Investigating an amino acid to improve medulloblastoma treatment
Looking at how medulloblastoma brain tumours use an amino acid, and whether blocking access to that resource would make cancer cells more susceptible to treatment.
Developing a kinder and more effective immunotherapy for neuroblastoma
Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.
Investigating why some children get leukaemia after treatment for other cancers
Looking at the early stages of leukaemia that develops after treatment for other cancers to find out what changes occur and how to fight it.
Investigating nanomedicines to make treatment safer for children with cancer
Looking at how nanoparticles could improve drug delivery and reduce toxicity for young cancer patients.
Assessing a potent drug combination to fight Wilms tumour
Using two drugs to prevent an essential Wilms tumour protein interacting with a growth-promoting protein, and testing this treatment in patient samples.